Aims: Venglustat is an oral glucosylceramide synthase inhibitor under clinical investigation to treat various lysosomal storage diseases. Metabolism is a main pathway for its elimination in humans with CYP3A being the major contributor. This study aims to evaluate effect of CYP3A inhibition (using itraconazole) on venglustat exposure and to develop and validate a physiologically based pharmacokinetic (PBPK) model to assess effects of additional CYP3A inhibitors of varying potencies on venglustat pharmacokinetics.
Methods: An open-label, single-sequence, 2-period drug-drug interaction (DDI) study was conducted in healthy subjects with coadministration of multiple twice daily oral doses of 100 mg itraconazole against a single dose of 15 mg venglustat. A minimal PBPK model was developed using available physicochemical, in vitro and in vivo pharmacokinetic data and validated using data from relevant venglustat clinical studies including the itraconazole DDI study. Effects of additional CYP3A inhibitors on venglustat exposure were predicted.
Results: Coadministration with itraconazole increased venglustat area under the concentration-time curve by 2.03-fold (90% confidence interval [90%CI]: 1.81-2.27). Venglustat steady-state area under the concentration-time curve during a dosing interval following coadministration with strong (clarithromycin), moderate (fluconazole) and weak (fluvoxamine and cimetidine; with CYP2D6 inhibition turned off) CYP3A inhibitors is predicted to increase by 1.74- (5th-95th centile, 1.30-2.49), 1.52- (1.23-1.88), 1.08- (1.03-1.15) and 1.08-fold (1.04-1.12), respectively.
Conclusion: The effect of itraconazole on venglustat exposure was quantified clinically, and a minimal PBPK model was successfully developed, validated and applied to assess DDI effect of additional CYP3A inhibitors on venglustat. The results help to further understand the DDI potential with venglustat and will inform dose recommendations with comedications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/bcp.70037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Caffeine-clarithromycin coadministration and hyperlactatemia in a young infant: a case report.
Crit Care Sci
March 2025
Division of Critical Care Medicine, Department of Pediatrics, Hospital das Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo - São Paulo (SP), Brazil.
Apnea is a major complication of acute respiratory tract infection in young infants and may lead to the need for ventilatory support. Caffeine is methylxanthine, which is considered the mainstay of pharmacologic treatment for apnea of prematurity. On the basis of neonatal guidelines, caffeine has been used as a respiratory stimulant for the treatment of acute respiratory tract infection-related apnea, despite low evidence of its ability to improve clinical outcomes.
View Article and Find Full Text PDF[Atelectasis caused by mucus stasis].
Ned Tijdschr Geneeskd
March 2025
Zaans Medisch Centrum, afd. Intensive Care, Zaandam.
A 58-year-old female presented at the emergency department with dyspnea. Laboratory and X-ray analyses showed eosinophilia and a partial atelectasis of the left lung, respectively. Bronchoscopy demonstrated mucus plugs.
View Article and Find Full Text PDFAirway-centered invasive pulmonary aspergillosis featuring histopathologic fruiting bodies in an immunocompetent patient with a rare incidental finding of thyroid gland Schwannoma: a case report.
BMC Infect Dis
March 2025
Department of Infectious diseases, University of Louisville Hospital, Louisville, USA.
Introduction: Invasive pulmonary aspergillosis (IPA) is typically associated with immunocompromised patients, but rare occurrences have been documented in immunocompetent individuals. This presents diagnostic and therapeutic challenges due to atypical presentations and less apparent risk factors.
Case Presentation: A 67-year-old Cambodian American female with a history of stable pulmonary nodules and a left neck schwannoma presented with a two-week history of cough and hemoptysis.
Deep cutaneous fungal infection in an immunocompetent individual caused by a biological pesticide: a rare case report.
BMC Infect Dis
March 2025
Department of Medical Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Background: Purpureocillium lilacinum is a type of fungus that is found all over the world and is known for its ability to help control pests, especially those that harm plants. Generally, this fungus does not cause serious problems for healthy people, but it can lead to severe infections in individuals with weakened immune systems. In this report, we discuss a rare case where a healthy person developed an infection after being exposed to a biopesticide containing this fungus.
View Article and Find Full Text PDFDrug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics.
Br J Clin Pharmacol
March 2025
Pharmacokinetics, Dynamics and Metabolism, Sanofi, Shanghai, China.
Aims: Venglustat is an oral glucosylceramide synthase inhibitor under clinical investigation to treat various lysosomal storage diseases. Metabolism is a main pathway for its elimination in humans with CYP3A being the major contributor. This study aims to evaluate effect of CYP3A inhibition (using itraconazole) on venglustat exposure and to develop and validate a physiologically based pharmacokinetic (PBPK) model to assess effects of additional CYP3A inhibitors of varying potencies on venglustat pharmacokinetics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!